

| | | | | |
|---|---|---|--------------------|------------------|
| Patient ID SA00118937 | Patient Name SAMPLEREPORT, FNMEN NORMAL | Birth Date 1985-01-22 | Gender M | Age 34 |
| Order Number SA00118937 | Client Order Number SA00118937 | Ordering Physician CLIENT, CLIENT | Report Notes | |
| Account Information C7028846 DLMP Rochester | | Collected 24 Mar 2019 00:00 | | |

N. meningitidis IgG Vacc Response

| | | | |
|------------------------|------|--------------------|------|
| Serogroup A | Y038 | Serogroup Y | Y038 |
| 5.0 ug/mL | | 4.5 ug/mL | |
| Serogroup C | Y038 | | |
| 6.0 ug/mL | | | |
| Serogroup W-135 | | | Y038 |
| 3.0 ug/mL | | | |

REFERENCE RANGES (PRE-VACCINATION) :

| | |
|-----------------|------------|
| Serogroup A | <4.0 ug/mL |
| Serogroup C | <5.0 ug/mL |
| Serogroup Y | <4.0 ug/mL |
| Serogroup W-135 | <3.0 ug/mL |

This assay measures serum IgG antibodies recognizing polysaccharide antigens from the four Neisseria meningitidis serogroups included in the licensed meningococcal vaccine response is best evaluated by testing pre-vaccination and post-vaccination samples in parallel. A two-fold or greater increase for at least two serogroups is expected when comparing post-vaccination to pre-vaccination results. N. meningitidis IgG levels peak approximately one month post-vaccination, but decline markedly by two years.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Received: 25 Mar 2019 08:01

Reported: 25 Mar 2019 11:38

Performing Site Legend

| Code | Laboratory | Address | Lab Director | CLIA Certificate |
|------|--------------------------------------|---|--------------|------------------|
| Y038 | Quest Diagnostics Infectious Disease | 33608 Ortega Highway, San Juan Capistrano, CA 92675 | | |